OUTLOOK THERAPEUTICS Financials
OTLK Stock | USD 2.01 0.31 18.24% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.64 | 0.6443 |
|
|
The essential information of the day-to-day investment outlook for OUTLOOK THERAPEUTICS includes many different criteria found on its balance sheet. An individual investor should monitor OUTLOOK THERAPEUTICS's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in OUTLOOK THERAPEUTICS.
Net Income |
|
OUTLOOK | Select Account or Indicator |
OUTLOOK THERAPEUTICS Stock Summary
OUTLOOK THERAPEUTICS competes with Fate Therapeutics, and Caribou Biosciences. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Outlook Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US69012T2069 |
CUSIP | 69012T206 69012T305 68235M105 69012T107 68235M204 |
Location | New Jersey; U.S.A |
Business Address | Building F, Iselin, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.outlooktherapeutics.com |
Phone | 609 619 3990 |
Currency | USD - US Dollar |
OUTLOOK THERAPEUTICS Key Financial Ratios
Return On Equity | -0.0365 | ||||
Price To Sales | 13.27 X | ||||
Gross Profit | (42.33 M) | ||||
EBITDA | (57.38 M) | ||||
Net Income | (58.98 M) |
OUTLOOK THERAPEUTICS Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 19.7M | 22.8M | 28.5M | 32.3M | 37.1M | 25.7M | |
Other Current Liab | 3.8M | 1.7M | 3.4M | 2.7M | 2.5M | 4.5M | |
Other Liab | 4.2M | 70.8K | 522.9K | 57.1K | 51.4K | 48.9K | |
Net Tangible Assets | (16.1M) | 2.8M | 4.6M | 8.7M | 10.0M | 10.5M | |
Net Debt | (3.7M) | (2.6M) | (6.4M) | 12.2M | 10.9M | 5.9M | |
Retained Earnings | (289.7M) | (342.9M) | (408.9M) | (467.9M) | (421.1M) | (400.1M) | |
Accounts Payable | 2.4M | 2.2M | 3.5M | 6.6M | 5.9M | 4.1M | |
Cash | 12.5M | 14.5M | 17.4M | 23.4M | 26.9M | 28.2M | |
Other Assets | 449.0 | (451.0) | 132.0K | 399.0 | 359.1 | 341.15 | |
Long Term Debt | 98.5K | 50.3K | 904.2K | 10.9M | 12.5M | 13.1M | |
Other Current Assets | 4.6M | 7.0M | 10.1M | 7.6M | 8.7M | 8.3M | |
Total Liab | 16.9M | 18.2M | 19.8M | 46.7M | 42.1M | 28.2M | |
Short Long Term Debt | 3.7M | 904.2K | 10.9M | 35.6M | 40.9M | 42.9M | |
Total Current Assets | 17.9M | 21.5M | 27.5M | 31.0M | 35.6M | 37.4M | |
Short Term Debt | 7.9M | 973.5K | 11.0M | 35.6M | 40.9M | 42.9M | |
Common Stock | 1.3M | 1.8M | 2.3M | 2.6M | 2.3M | 3.9M | |
Long Term Debt Total | 3.6M | 3.4M | 904.2K | 10.9M | 12.5M | 6.4M | |
Capital Surpluse | 238.1M | 291.3M | 345.7M | 415.4M | 477.7M | 278.9M |
OUTLOOK THERAPEUTICS Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 1.8M | 936K | 1.5M | 1.6M | 1.4M | 1.9M | |
Gross Profit | (554.1K) | (262.1K) | (204.7K) | (44.2K) | (39.8K) | (37.8K) | |
Operating Income | (36.8M) | (51.7M) | (63.1M) | (53.1M) | (47.8M) | (50.2M) | |
Ebit | (36.3M) | (51.7M) | (63.1M) | (57.4M) | (51.7M) | (54.3M) | |
Research Development | 26.3M | 39.0M | 42.3M | 26.5M | 30.4M | 31.5M | |
Ebitda | (35.8M) | (51.5M) | (62.9M) | (57.4M) | (51.6M) | (54.2M) | |
Cost Of Revenue | 554.1K | 262.1K | 204.7K | 44.2K | 50.8K | 48.3K | |
Income Before Tax | (38.5M) | (53.2M) | (66.0M) | (59.0M) | (53.1M) | (55.7M) | |
Net Income | (35.2M) | (53.2M) | (66.1M) | (59.0M) | (53.1M) | (55.7M) | |
Income Tax Expense | (3.4M) | (3.3M) | 2K | 2.8K | 2.5K | 2.6K | |
Tax Provision | (3.3M) | 2K | 2.8K | 3K | 2.7K | 2.8K | |
Net Interest Income | (1.8M) | (936.1K) | (1.5M) | (1.6M) | (1.8M) | (1.9M) |
OUTLOOK THERAPEUTICS Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 4.5M | 1.9M | 2.9M | 6.0M | 6.9M | 7.2M | |
Net Borrowings | (6.9M) | 856.0K | 6.3M | (2.9M) | (2.6M) | (2.5M) | |
Free Cash Flow | (31.8M) | (54.3M) | (56.7M) | (43.0M) | (38.7M) | (40.6M) | |
Depreciation | 554.1K | 262.1K | 204.7K | 44.2K | 39.8K | 37.8K | |
Other Non Cash Items | (881.3K) | 341.5K | 3.1M | 5.7M | 6.5M | 6.8M | |
Capital Expenditures | 2.8M | 437.3K | 0.0 | 2.0 | 1.8 | 1.71 | |
Net Income | (35.2M) | (53.2M) | (66.1M) | (59.0M) | (53.1M) | (55.7M) | |
End Period Cash Flow | 12.5M | 14.5M | 17.4M | 23.4M | 26.9M | 28.2M | |
Change To Netincome | 12.1M | 5.3M | 6.3M | 10.0M | 11.5M | 9.1M |
OUTLOOK Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining OUTLOOK THERAPEUTICS's current stock value. Our valuation model uses many indicators to compare OUTLOOK THERAPEUTICS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across OUTLOOK THERAPEUTICS competition to find correlations between indicators driving OUTLOOK THERAPEUTICS's intrinsic value. More Info.OUTLOOK THERAPEUTICS INC is considered to be number one stock in return on equity category among its peers. It is regarded third in return on asset category among its peers . At this time, OUTLOOK THERAPEUTICS's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value OUTLOOK THERAPEUTICS by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.OUTLOOK THERAPEUTICS INC Systematic Risk
OUTLOOK THERAPEUTICS's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. OUTLOOK THERAPEUTICS volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on OUTLOOK THERAPEUTICS INC correlated with the market. If Beta is less than 0 OUTLOOK THERAPEUTICS generally moves in the opposite direction as compared to the market. If OUTLOOK THERAPEUTICS Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one OUTLOOK THERAPEUTICS INC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of OUTLOOK THERAPEUTICS is generally in the same direction as the market. If Beta > 1 OUTLOOK THERAPEUTICS moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in OUTLOOK THERAPEUTICS Stock are looking for potential investment opportunities by analyzing not only static indicators but also various OUTLOOK THERAPEUTICS's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of OUTLOOK THERAPEUTICS growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
OUTLOOK THERAPEUTICS December 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of OUTLOOK THERAPEUTICS help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of OUTLOOK THERAPEUTICS INC. We use our internally-developed statistical techniques to arrive at the intrinsic value of OUTLOOK THERAPEUTICS INC based on widely used predictive technical indicators. In general, we focus on analyzing OUTLOOK Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build OUTLOOK THERAPEUTICS's daily price indicators and compare them against related drivers.
Information Ratio | (0.08) | |||
Maximum Drawdown | 72.39 | |||
Value At Risk | (8.29) | |||
Potential Upside | 11.84 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OUTLOOK THERAPEUTICS INC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.06) | Revenue Per Share 0.119 | Quarterly Revenue Growth 6.583 | Return On Assets (0.84) | Return On Equity (0.04) |
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.